LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Mitoxantrone | 0.12 | uM | LJP6 | 3 | C23 | 72 | hr | 868 | 848 | 3486 | 0.2432 | -0.0077 |
MDA-MB-231 | MK2206 | 0.12 | uM | LJP6 | 1 | F05 | 72 | hr | 868 | 3095 | 3486 | 0.8877 | 0.8505 |
MDA-MB-231 | MK2206 | 0.12 | uM | LJP6 | 2 | F05 | 72 | hr | 868 | 2890 | 3486 | 0.8289 | 0.7722 |
MDA-MB-231 | MK2206 | 0.12 | uM | LJP6 | 3 | F05 | 72 | hr | 868 | 3291 | 3486 | 0.9440 | 0.9254 |
MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 1 | A17 | 72 | hr | 868 | 2358 | 3486 | 0.6763 | 0.5690 |
MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 2 | A17 | 72 | hr | 868 | 2438 | 3486 | 0.6993 | 0.5996 |
MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 3 | A17 | 72 | hr | 868 | 2568 | 3486 | 0.7366 | 0.6492 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 868 | 2580 | 3486 | 0.7400 | 0.6538 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 868 | 2806 | 3486 | 0.8048 | 0.7401 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 868 | 2971 | 3486 | 0.8522 | 0.8032 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 1 | H05 | 72 | hr | 868 | 3249 | 3486 | 0.9319 | 0.9093 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 2 | H05 | 72 | hr | 868 | 3849 | 3486 | 1.1040 | 1.1385 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 3 | H05 | 72 | hr | 868 | 3824 | 3486 | 1.0968 | 1.1289 |
MDA-MB-231 | NU7441 | 0.12 | uM | LJP5 | 1 | C11 | 72 | hr | 868 | 3336 | 3486 | 0.9569 | 0.9426 |
MDA-MB-231 | NU7441 | 0.12 | uM | LJP5 | 2 | C11 | 72 | hr | 868 | 2964 | 3486 | 0.8502 | 0.8005 |
MDA-MB-231 | NU7441 | 0.12 | uM | LJP5 | 3 | C11 | 72 | hr | 868 | 3528 | 3486 | 1.0119 | 1.0159 |
MDA-MB-231 | Dactolisib | 0.12 | uM | LJP5 | 1 | M17 | 72 | hr | 868 | 1697 | 3486 | 0.4868 | 0.3166 |
MDA-MB-231 | Dactolisib | 0.12 | uM | LJP5 | 2 | M17 | 72 | hr | 868 | 1914 | 3486 | 0.5490 | 0.3995 |
MDA-MB-231 | Dactolisib | 0.12 | uM | LJP5 | 3 | M17 | 72 | hr | 868 | 1823 | 3486 | 0.5229 | 0.3647 |
MDA-MB-231 | NVP-TAE684 | 0.12 | uM | LJP6 | 1 | K17 | 72 | hr | 868 | 2158 | 3486 | 0.6190 | 0.4926 |
MDA-MB-231 | NVP-TAE684 | 0.12 | uM | LJP6 | 2 | K17 | 72 | hr | 868 | 2464 | 3486 | 0.7068 | 0.6095 |
MDA-MB-231 | NVP-TAE684 | 0.12 | uM | LJP6 | 3 | K17 | 72 | hr | 868 | 2310 | 3486 | 0.6626 | 0.5507 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 1 | E17 | 72 | hr | 868 | 2447 | 3486 | 0.7019 | 0.6030 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 2 | E17 | 72 | hr | 868 | 2402 | 3486 | 0.6890 | 0.5858 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 3 | E17 | 72 | hr | 868 | 2166 | 3486 | 0.6213 | 0.4957 |